These results indicated poor outcomes for BLCA and LIHC patients with relatively higher expression of C12orf75, and the relationship between C12orf75 and papillary/nonpapillary track oncogenic pathways needs to be confirmed in further studies. This evidence concerns the gene C12orf75 and bladder transitional cell carcinoma.